Drug intelligence / Profile preview

V-930

Development stage: Phase 1
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

V-930 is an experimental vaccine developed by Merck Sharp & Dohme LLC. It is designed to elicit an immune response against cancer cells that express tumor antigens such as Human Epidermal Growth Factor Receptor 2 (HER-2) and Carcinoembryonic Antigen (CEA). The vaccine is administered via intramuscular injection, often followed by electrostimulation using a device like the MedPulser DDS, a technique intended to enhance its immunogenicity and therapeutic effect.

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on V-930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-930.

Explore the full profile